These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Comparative study on the pharmacokinetics of 7-hydroxy-methotrexate after administration of methotrexate in the dose range of 0.5-33.6 g/m2 to children with acute lymphoblastic leukemia. Borsi JD; Sagen E; Romslo I; Moe PJ Med Pediatr Oncol; 1990; 18(3):217-24. PubMed ID: 2329967 [TBL] [Abstract][Full Text] [Related]
24. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645 [TBL] [Abstract][Full Text] [Related]
26. Biliary elimination of low-dose methotrexate in humans. Nuernberg B; Koehnke R; Solsky M; Hoffman J; Furst DE Arthritis Rheum; 1990 Jun; 33(6):898-902. PubMed ID: 2363742 [TBL] [Abstract][Full Text] [Related]
27. Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. Hartmann SN; Rordorf CM; Milosavljev S; Branson JM; Chales GH; Juvin RR; Lafforgue P; Le Parc JM; Tavernier CG; Meyer OC Ann Pharmacother; 2004 Oct; 38(10):1582-7. PubMed ID: 15340127 [TBL] [Abstract][Full Text] [Related]
28. Dose-dependent pharmacokinetics of methotrexate and 7-hydroxymethotrexate in the rat in vivo. Bremnes RM; Slørdal L; Wist E; Aarbakke J Cancer Res; 1989 Nov; 49(22):6359-64. PubMed ID: 2804982 [TBL] [Abstract][Full Text] [Related]
29. Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study. Punt CJ; Kamm YL; Wagener DJ Anticancer Drugs; 1997 Jun; 8(5):454-8. PubMed ID: 9215607 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Breithaupt H; Küenzlen E Cancer Treat Rep; 1982 Sep; 66(9):1733-41. PubMed ID: 6956440 [TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution. Zhang W; Zhang Q; Tian X; Zhao H; Lu W; Zhen J; Niu X Chin Med J (Engl); 2015 Jan; 128(1):111-8. PubMed ID: 25563323 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. Sonneveld P; Schultz FW; Nooter K; Hählen K Cancer Chemother Pharmacol; 1986; 18(2):111-6. PubMed ID: 3791556 [TBL] [Abstract][Full Text] [Related]
33. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. Stoller RG; Hande KR; Jacobs SA; Rosenberg SA; Chabner BA N Engl J Med; 1977 Sep; 297(12):630-4. PubMed ID: 302412 [TBL] [Abstract][Full Text] [Related]
34. Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion. Creinin MD; Krohn MA Am J Obstet Gynecol; 1997 Dec; 177(6):1444-9. PubMed ID: 9423749 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Pignon T; Lacarelle B; Duffaud F; Guillet P; Catalin J; Durand A; Monjanel S; Favre R Cancer Chemother Pharmacol; 1994; 33(5):420-4. PubMed ID: 8306417 [TBL] [Abstract][Full Text] [Related]
36. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545 [TBL] [Abstract][Full Text] [Related]
37. 42-hour methotrexate infusions as relapse therapy for childhood malignancies: toxicity and efficacy of 109 infusions. Bode U; Erps M; Schiffer D Pediatr Hematol Oncol; 1987; 4(1):15-24. PubMed ID: 3152909 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of leucovorin (D,L-5-formyltetrahydrofolate) after intravenous injection and constant intravenous infusion. Straw JA; Newman EM; Doroshow JH NCI Monogr; 1987; (5):41-5. PubMed ID: 3501545 [TBL] [Abstract][Full Text] [Related]
39. Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion. Wang YM; Kim PY; Lantin E; van Eys DC; Romsdahl MM; Sutow WW Med Pediatr Oncol; 1978; 4(3):221-9. PubMed ID: 308151 [TBL] [Abstract][Full Text] [Related]